{"id":826320,"date":"2025-03-17T08:47:16","date_gmt":"2025-03-17T12:47:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/"},"modified":"2025-03-17T08:47:16","modified_gmt":"2025-03-17T12:47:16","slug":"china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/","title":{"rendered":"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TAIZHOU, China, March  17, 2025  (GLOBE NEWSWIRE) &#8212;  China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the \u201cCompany\u201d), \u00a0a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (\u201cTCMPs\u201d), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (\u201cTCMHS\u201d), today announced that the Company received a written notification (the \u201cCompliance Notice\u201d) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (\u201cMinimum Bid Price Requirement\u201d) and the matter is closed.<\/p>\n<p align=\"justify\">As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days under Minimum Bid Price Requirement. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company was provided with 180 calendar days, or until April 1, 2025, to regain compliance.<\/p>\n<p align=\"justify\">To comply with the Minimum Bid Price Requirement, the closing bid price of the Company\u2019s ordinary shares must be at least US$1.00 per share for a minimum of 10 consecutive business days at any time prior to April 1, 2025. Therefore, in order to cure the Minimum Bid Price deficiency, the Company has effectuated a share consolidation on February 25, 2025, of which every eight (8) issued and unissued ordinary shares of the Company with no par value each be consolidated into one (1) share with no par value.<\/p>\n<p align=\"justify\">According to the Compliance Notice, the Company evidenced a closing bid price of its ordinary shares at or greater than US$1.00 per share for 10 consecutive business days from February 25, 2025 to March 12, 2025. Thus, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is closed.<\/p>\n<p>\n        <strong>About China SXT Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FwlpbWq5r7G-1k2OS9SmhyFrc4_EPr4NReyogKHQVhIE0wo8RS4_pQvxh9O5C2JWBq-OOiU3tj7gkdXRIX7oGjZkWFYHoKljHptOnkIPBAc=\" rel=\"nofollow\" target=\"_blank\"><u>www.sxtchina.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements include, among others, statements regarding the Company\u2019s plans to regain compliance with the minimum bid price requirement. The Company\u2019s actual results may differ materially from those expressed in any forward-looking statements as a result of various factors and uncertainties. The reports filed by the Company with the Securities and Exchange Commission discuss these and other important factors and risks that may affect the Company\u2019s business, results of operations and financial conditions. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.<\/p>\n<p>\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<p>Feng Zhou, Chief Executive Officer<\/p>\n<p>Email:\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=coP4MoC7RExevJeesMcBD0TROx79AeDBc7bBJd9CS3e3ppOczWZK3rW9k_uB1KLHgt9ZL9uPipCWBtnvUd7EKDoLlxLZlt7tlEvxAU7R9xg=\" rel=\"nofollow\" target=\"_blank\">fzhou@sxtchina.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzE4YzJkMDEtNjgwNi00YzYwLTg0OGEtZTk2NmJjODhjNGY2LTUwMDA5OTEzNy0yMDI1LTAzLTE3LWVu\/tiny\/China-SXT-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) &#8212; China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the \u201cCompany\u201d), \u00a0a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (\u201cTCMPs\u201d), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (\u201cTCMHS\u201d), today announced that the Company received a written notification (the \u201cCompliance Notice\u201d) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (\u201cMinimum Bid Price Requirement\u201d) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826320","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) &#8212; China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the \u201cCompany\u201d), \u00a0a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (\u201cTCMPs\u201d), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (\u201cTCMHS\u201d), today announced that the Company received a written notification (the \u201cCompliance Notice\u201d) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (\u201cMinimum Bid Price Requirement\u201d) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating &hellip; Continue reading &quot;China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T12:47:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency\",\"datePublished\":\"2025-03-17T12:47:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/\"},\"wordCount\":532,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/\",\"name\":\"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==\",\"datePublished\":\"2025-03-17T12:47:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/","og_locale":"en_US","og_type":"article","og_title":"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency - Market Newsdesk","og_description":"TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) &#8212; China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the \u201cCompany\u201d), \u00a0a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (\u201cTCMPs\u201d), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (\u201cTCMHS\u201d), today announced that the Company received a written notification (the \u201cCompliance Notice\u201d) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (\u201cMinimum Bid Price Requirement\u201d) and the matter is closed. As previously announced, the Company received a notification letter from the Nasdaq dated October 3, 2024, indicating &hellip; Continue reading \"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-17T12:47:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency","datePublished":"2025-03-17T12:47:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/"},"wordCount":532,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/","name":"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==","datePublished":"2025-03-17T12:47:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTUwMyM2ODA5MTU0IzUwMDA5OTEzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/china-sxt-pharmaceuticals-has-regained-compliance-with-nasdaqs-minimum-bid-price-deficiency\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"China SXT Pharmaceuticals Has Regained Compliance with Nasdaq\u2019s Minimum Bid Price Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826320"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826320\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}